Phase I Trial of Weekly and Twice-Weekly Bortezomib with Rituximab, Cyclophosphamide, and Prednisone in Relapsed or Refractory non-Hodgkin Lymphoma

PURPOSE: To determine the safety and efficacy of substituting weekly or twice weekly bortezomib for vincristine in the R-CVP regimen (rituximab, cyclophosphamide, vincristine, prednisone) in patients with relapsed/refractory indolent and mantle cell lymphoma. EXPERIMENTAL DESIGN: Of the 57 patients...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Gerecitano, John, Portlock, Carol, Hamlin, Paul, Moskowitz, Craig H., Noy, Ariela, Straus, David, Schulman, Philip, Dumitrescu, Otilia, Sarasohn, Debra, Pappanicholaou, Jennifer, Iasonos, Alexia, Zhang, Zhigang, Mo, Qianxing, Horanlli, Endri, Rojas, Celeste N., Zelenetz, Andrew D., O’Connor, Owen. A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2011
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5639472/
https://ncbi.nlm.nih.gov/pubmed/21346146
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-10-1498
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados